PFKFB4 as a promising biomarker to predict a poor prognosis in patients with gastric cancer

Wang,Fang; Wu,Xiaoting; Li,Yajun; Cao,Xiangmei; Zhang,Cao; Gao,Yujing

doi:10.3892/ol.2021.12557

PFKFB4 as a promising biomarker to predict a poor prognosis in patients with gastric cancer

Authors:
- Fang Wang
- Xiaoting Wu
- Yajun Li
- Xiangmei Cao
- Cao Zhang
- Yujing Gao
View Affiliations

Affiliations: Department of Gastroenterology, General Hospital of Ningxia Medical University, Ningxia Medical University, Yinchuan, Ningxia 750004, P.R. China, Department of Pathology, School of Basic Medical Sciences, Ningxia Medical University, Yinchuan, Ningxia 750004, P.R. China, Department of General Surgery, General Hospital of Ningxia Medical University, Ningxia Medical University, Yinchuan, Ningxia 750004, P.R. China, Key Laboratory of Fertility Preservation and Maintenance of Ministry of Education, Department of Biochemistry and Molecular Biology, Ningxia Medical University, Yinchuan, Ningxia 750004, P.R. China
Published online on: February 17, 2021 https://doi.org/10.3892/ol.2021.12557
Article Number: 296
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gastric cancer (GC) is one of the most common types of cancer worldwide. Previous studies have reported that phosphofructo‑2‑kinase/fructose‑2,6‑biphosphatase 4 (PFKFB4) functions as an oncoprotein in various types of cancer. However, the association between PFKFB4 and GC remains unclear. The present study analyzed the expression levels of PFKFB4 in 148 GC tissue samples, including 46 tumor tissues with matched adjacent normal tissues, using immunohistochemistry, compared the expression levels of PFKFB4 between GC and adjacent normal tissues, and determined the association between PFKFB4 expression levels and patient clinicopathological characteristics. In addition, survival curves were generated using the Kaplan‑Meier (KM) plotter database to evaluate the association between PFKFB4 expression and GC prognosis. The results revealed that PFKFB4 expression was upregulated in GC tissues compared with in adjacent normal tissues. PFKFB4 expression was associated with patient age, tumor size, pathological tumor (pT) stage and tumor‑node‑metastasis (pTNM) stage, and upregulated expression levels of PFKFB4 were observed in tumor tissues from patients <65 years old (compared with that in patients ≥65 years old), as well as patients with a larger tumor size and an advanced stage (pT and pTNM stage) disease. In addition, KM survival analysis demonstrated that patients with low PFKFB4 expression had a significantly improved overall survival (OS), first progression survival and post‑progression survival times compared with those with high PFKFB4 expression. Furthermore, PFKFB4 expression was negatively associated with OS time in patients with late pT and pTNM stage disease. In conclusion, the results of the present study indicated that the upregulated PFKFB4 expression in GC tissues may serve as a biomarker for a more advanced disease and a poor prognosis in patients with GC.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Cheng C, Zhang Q, Zhuang L and Sun J: Prognostic value of lymphocyte-to-C-reactive protein ratio in patients with gastric cancer after surgery: A multicentre study. Jpn J Clin Oncol. 50:1141–1149. 2020. View Article : Google Scholar : PubMed/NCBI
3	Maeda K, Shibutani M, Otani H, Nagahara H, Ikeya T, Iseki Y, Tanaka H, Muguruma K and Hirakawa K: Inflammation-based factors and prognosis in patients with colorectal cancer. World J Gastrointest Oncol. 7:111–117. 2015. View Article : Google Scholar : PubMed/NCBI
4	Liu H, Zhao YR, Chen B, Ge Z and Huang JS: High expression of SMARCE1 predicts poor prognosis and promotes cell growth and metastasis in gastric cancer. Cancer Manag Res. 11:3493–3509. 2019. View Article : Google Scholar : PubMed/NCBI
5	Zhang XG, Song BT, Liu FJ, Sun D, Wang KX and Qu H: CCR6 overexpression predicted advanced biological behaviors and poor prognosis in patients with gastric cancer. Clin Transl Oncol. 18:700–707. 2016. View Article : Google Scholar : PubMed/NCBI
6	Koppenol WH, Bounds PL and Dang CV: Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer. 11:325–327. 2011. View Article : Google Scholar : PubMed/NCBI
7	Lai W, Wang Z and Liang HJ: Expression of 6-phosphofructokinase-2 in colorectal cancer and its clinical significance. J Third Military Med University (Chinese). 39:983–989. 2017.
8	Chesney J, Clark J, Klarer AC, Imbert-Fernandez Y, Lane AN and Telang S: Fructose-2,6-bisphosphate synthesis by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 (PFKFB4) is required for the glycolytic response to hypoxia and tumor growth. Oncotarget. 5:6670–6686. 2014. View Article : Google Scholar : PubMed/NCBI
9	Li XM and Li W: Progress in the study on the role of PFKFB4 and potential mechanism in tumor glucose metabolism. Chin J N Clin Med. 11:1044–1048. 2018.
10	Li W, Qian L, Lin J, Huang G, Hao N, Wei X, Wang W and Liang J: CD44 regulates prostate cancer proliferation, invasion and migration via PDK1 and PFKFB4. Oncotarget. 8:65143–65151. 2017. View Article : Google Scholar : PubMed/NCBI
11	Wang M and Sun TY: Effects of PFKFB4 on invasion and migration of gastric cancer cells and its mechanism. J Pract Oncol (Chinese). 34:229–234. 2020.
12	Washington K: 7th Edition of the AJCC cancer staging manual: Stomach. Ann Surg Oncol. 17:3077–3079. 2010. View Article : Google Scholar : PubMed/NCBI
13	Xu L and Yang WT: The judgement standard of immunohistochemical reaction results. Chin Oncol. 6:229–231. 1996.
14	Gao R, Liu Y, Li D, Xun J, Zhou W, Wang P, Liu C, Li X, Shen W, Su W, et al: PFKFB4 promotes breast cancer metastasis via induction of hyaluronan production in a p38-Dependent manner. Cell Physiol Biochem. 50:2108–2123. 2018. View Article : Google Scholar : PubMed/NCBI
15	Li X, Chen Z, Li Z, Huang G, Lin J, Wei Q, Liang J and Li W: The metabolic role of PFKFB4 in androgen-independent growth in vitro and PFKFB4 expression in human prostate cancer tissue. BMC Urol. 20:612020. View Article : Google Scholar : PubMed/NCBI
16	Zhang H, Lu C, Fang M, Yan W, Chen M, Ji Y, He S, Liu T, Chen T and Xiao J: HIF-1α activates hypoxia-induced PFKFB4 expression in human bladder cancer cells. Biochem Biophys Res Commun. 476:146–152. 2016. View Article : Google Scholar : PubMed/NCBI
17	Lu H, Chen S, You Z, Xie C, Huang S and Hu X: PFKFB4 negatively regulated the expression of histone acetyltransferase GCN5 to mediate the tumorigenesis of thyroid cancer. Dev Growth Differ. 62:129–138. 2020. View Article : Google Scholar : PubMed/NCBI
18	Chesney J, Clark J, Lanceta L, Trent JO and Telang S: Targeting the sugar metabolism of tumors with a first-in-class 6-phosphofructo-2-kinase (PFKFB4) inhibitor. Oncotarget. 6:18001–18011. 2015. View Article : Google Scholar : PubMed/NCBI
19	Minchenko OH, Tsuchihara K, Minchenko DO, Bikfalvi A and Esumi H: Mechanisms of regulation of PFKFB expression in pancreatic and gastric cancer cells. World J Gastroenterol. 20:13705–13717. 2014. View Article : Google Scholar : PubMed/NCBI
20	Ros S, Floter J, Kaymak I, Da Costa C, Houddane A, Dubuis S, Griffiths B, Mitter R, Walz S, Blake S, et al: 6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 is essential for p53-null cancer cells. Oncogene. 36:3287–3299. 2017. View Article : Google Scholar : PubMed/NCBI
21	Shu Y, Lu Y, Pang X, Zheng W, Huang Y, Li J, Ji J, Zhang C and Shen P: Phosphorylation of PPARg at Ser84 promotes glycolysis and cell proliferation in hepatocellular carcinoma by targeting PFKFB4. Oncotarget. 7:76984–76994. 2016. View Article : Google Scholar : PubMed/NCBI
22	Gao R, Li D, Xun J, Zhou W, Li J, Wang J, Liu C, Li X, Shen W, Qiao H, et al: CD44ICD promotes breast cancer stemness via PFKFB4-mediated glucose metabolism. Theranostics. 8:6248–6262. 2018. View Article : Google Scholar : PubMed/NCBI
23	Trojan SE, Piwowar M, Ostrowska B, Laidler P and Kocemba-Pilarczyk KA: Analysis of malignant melanoma cell lines exposed to hypoxia reveals the importance of PFKFB4 overexpression for disease progression. Anticancer Res. 38:6745–6752. 2018. View Article : Google Scholar : PubMed/NCBI
24	Wang Q, Zeng F, Sun Y, Qiu Q, Zhang J, Huang W, Huang J, Huang X and Guo L: Etk interaction with PFKFB4 modulates chemoresistance of small-cell lung cancer by regulating autophagy. Clin Cancer Res. 24:950–962. 2018. View Article : Google Scholar : PubMed/NCBI
25	Dasgupta S, Rajapakshe K, Zhu B, Nikolai BC, Yi P, Putluri N, Choi JM, Jung SY, Coarfa C, Westbrook TF, et al: Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer. Nature. 556:249–254. 2018. View Article : Google Scholar : PubMed/NCBI
26	Yao L, Wang L, Cao ZG, Hu X and Shao ZM: High expression of metabolic enzyme PFKFB4 is associated with poor prognosis of operable breast cancer. Cancer Cell Int. 19:1652019. View Article : Google Scholar : PubMed/NCBI
27	Yun SJ, Jo SW, Ha YS, Lee OJ, Kim WT, Kim YJ, Lee SC and Kim WJ: PFKFB4 as a prognostic marker in non-muscle-invasive bladder cancer. Urol Oncol. 30:893–899. 2012. View Article : Google Scholar : PubMed/NCBI